Welcome to our dedicated page for Orthofix Med news (Ticker: OFIX), a resource for investors and traders seeking the latest updates and insights on Orthofix Med stock.
Orthofix Medical Inc. (OFIX) is a global leader in orthopedic and spinal medical devices, delivering innovative solutions for bone repair and spinal treatments. This dedicated news hub provides investors and healthcare professionals with timely updates on corporate developments, clinical advancements, and regulatory milestones.
Access comprehensive coverage of OFIX's latest press releases, earnings reports, and strategic initiatives. Track updates across key areas including spinal implant innovations, bone growth therapy research, and global partnership announcements. Our curated news collection serves as an essential resource for understanding market positioning and operational progress.
Stay informed about critical developments in Orthofix's core segments: Global Spine solutions addressing complex spinal disorders and Global Orthopedics technologies for fracture repair. The page aggregates verified updates on product launches, clinical trial outcomes, and regulatory approvals – all vital for assessing the company's trajectory.
Bookmark this page for streamlined access to OFIX's evolving story. Combine fundamental analysis with real-time updates to make informed decisions about this innovative medical device pioneer.
Orthofix, a global leader in spine and orthopedics, has won the 'Best Patient Experience Solution' award at the 2024 MedTech Breakthrough Awards for its STIM onTrack™ mobile app. The app, compatible with FDA-approved bone growth therapy devices like CervicalStim™, SpinalStim™, and PhysioStim™, tracks patient compliance data and aids in recovery by providing daily treatment reminders, usage calendars, and patient-reported outcome measures. The app enhances patient engagement by allowing remote monitoring and direct communication with physicians. This is Orthofix's second consecutive win at the MedTech Breakthrough Awards.
Orthofix Medical Inc. (NASDAQ:OFIX) has received FDA 510(k) clearance to market its innovative Rodeo Telescopic Nail designed to treat deformities or fractures in patients with osteogenesis imperfecta. The device stabilizes limbs and accommodates natural growth in pediatric patients, addressing biomechanical challenges in a streamlined procedure. The system enhances bone fixation in fragile OI patients, optimizes operational efficiency, reduces costs, and lessens contamination risks. This marks Orthofix's dedication to serving the pediatric market with tailored solutions for conditions like OI.
Orthofix Medical Inc. (NASDAQ:OFIX) reported strong first quarter 2024 results with net sales of $188.6 million, a 7.7% increase on a reported basis. The company saw growth across key segments, including Bone Growth Therapies, U.S. Spine Fixation, and Global Orthopedics. Despite a net loss of $36 million, the Non-GAAP Adjusted EBITDA increased to $7.7 million, showing a 220 basis point expansion. Orthofix raised its full-year net sales guidance to $790.0-$795.0 million, emphasizing continued growth and profitability.
FAQ
What is the current stock price of Orthofix Med (OFIX)?
What is the market cap of Orthofix Med (OFIX)?
